DIA: Driving Insights to Action
Science:Life Sciences
With more than 30 leading multinational pharmaceutical companies choosing Singapore as their base for operations in this region, this island nation has emerged as one of the most advanced biomedical R&D hubs in Asia. “The Singapore government understands the importance for Singapore, as a small country, to follow international standards,” explains Jin Shun, Head of Regulatory Affairs, Asia-Pacific, Middle East and Africa, for Sandoz, a Unit of Novartis. “HSA (the Health Sciences Authority) joined ICH in November 2017, and announced the implementation of eCTD at the end of last year.” Mr. Shun serves on the program committee for the DIA-CoRE Singapore Annual Meeting 2019.
Need for Value Creates Opportunity for Patients
Can Europe Optimize Healthcare Quality AND Pricing?
Rules for Successful Patient-Industry Engagement
Multiple Channels Can Share “One Medical Voice”
Advertising & Promotion: What You Can (and Can’t) Say
Could Precision Medicine Deliver “You on a Chip”?
“Enlightened Regulation” Illuminating Translational Science
Time and Place for Innovation in a Pandemic Outbreak?
SFDA Talks Drug Pricing & Shortages in Advance of MERC 2017
Translating Medical Information into Effective Communication
Tufts eClinical Study: Complexity Overrunning Technology
Post-Brexit PV in Europe “An Issue We Shouldn’t Underestimate”
CDER Director: Interest in How Patients Feel & Function
EU Clinical Trial Regulation Streamlines to "Matter of One"
The Gaps In Drug Pricing
Biosimilars’ Good News for Patients
Pace of Innovation vs. Regulation: Combination Challenge
Oligonucleotides Driving Personalized Medicine Research
Celebrating 150 Years with Better Care for Canadians
Future Science & Drug Review: FDA Closing the Gap
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Unexplainable
Stuff To Blow Your Mind
Terrace | تراس